Clinical Trials Directory

Trials / Completed

CompletedNCT03162198

Frequency of Circulating Tumor Cells (CTCs) and Amount of Cell-free DNA (cfDNA) in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)

Status
Completed
Phase
Study type
Observational
Enrollment
53 (actual)
Sponsor
Institute of Liver and Biliary Sciences, India · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

All consecutive patients with liver cirrhosis, with clinical and imaging features suggestive of Hepatocellular Carcinoma (HCC) attending the Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS) from February 2017 to December 2018 will be evaluated for inclusion.Based on the previous years data of HCC patients admitted to ILBS. Cirrhotic patients aged 18-70 years, with HCC proven by typical radiological features of arterial enhancement and delayed wash-out, on one or both of dynamic Computerized Tomographic or dynamic Magnetic Resonance Imaging (MRI), as per updated American Association for the Study of Liver Disease (AASLD) guidelines (details in appendix1). Age and gender matched patients with cirrhosis, but without HCC, seen during the same study period will serve as controls. Patient characteristics, etiology of cirrhosis, and liver function parameters will be noted. Investigator will stage the included patients as per the Barcelona Cancer of Liver Cancer (BCLC) criteria (details in appendix1). Investigator will then estimate Circulating Tumor Cells (CTC) and cfDNA in peripheral blood samples of the patients and controls.

Conditions

Interventions

TypeNameDescription
OTHERCirrhosis with HCCCirrhosis with Hepatocellular Carcinoma
OTHERCirrhosis without HCCCirrhosis without Hepatocellular Carcinoma

Timeline

Start date
2017-05-15
Primary completion
2018-10-31
Completion
2018-10-31
First posted
2017-05-22
Last updated
2019-10-23

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT03162198. Inclusion in this directory is not an endorsement.